LEPU ScienTech Medical Technology (Shanghai) Valuation

Is 2291 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 2291 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 2291 (HK$17.6) is trading below our estimate of fair value (HK$22.52)

Significantly Below Fair Value: 2291 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 2291?

Key metric: As 2291 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 2291. This is calculated by dividing 2291's market cap by their current earnings.
What is 2291's PE Ratio?
PE Ratio	26.3x
Earnings	CN¥216.19m
Market Cap	CN¥5.69b

2291 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	10.7x
Enterprise Value/EBITDA	17.3x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does 2291's PE Ratio compare to its peers?

The above table shows the PE ratio for 2291 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	23.8x
1789 AK Medical Holdings	29.8x	29.1%	HK$6.0b
2172 MicroPort NeuroScientific	21.3x	22.5%	HK$5.1b
1302 LifeTech Scientific	25.3x	29.5%	HK$6.8b
1858 Beijing Chunlizhengda Medical Instruments	18.7x	29.6%	HK$5.1b
2291 LEPU ScienTech Medical Technology (Shanghai)	26.3x	n/a	HK$6.1b

Price-To-Earnings vs Peers: 2291 is expensive based on its Price-To-Earnings Ratio (26.3x) compared to the peer average (23.8x).

Price to Earnings Ratio vs Industry

How does 2291's PE Ratio compare vs other companies in the HK Medical Equipment Industry?

1 Company	Price / Earnings	Estimated Growth	Market Cap
2393 Yestar Healthcare Holdings	0.1x	n/a	US$21.57m

No more companies available in this PE range

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 2291 is expensive based on its Price-To-Earnings Ratio (26.3x) compared to the Hong Kong Medical Equipment industry average (16x).

Price to Earnings Ratio vs Fair Ratio

What is 2291's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

2291 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	26.3x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 2291's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Hygeia Healthcare Holdings

HK$9.8b

Offers oncology healthcare services in the People's Republic of China.

6078

HK$15.80

-11.3%

-67.2%

Sinopharm Group

HK$62.7b

Engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People’s Republic of China.

1099

HK$20.10

-2.2%

3.7%